Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Shu-Kui Wang
The Effect of BIM Deletion Polymorphism on Intrinsic Resistance and Clinical Outcome of Cancer Patient With Kinase Inhibitor Therapy
Scientific Reports
Multidisciplinary
Prognostic Significance of Long Noncoding RNA Z38 as a Candidate Biomarker in Breast Cancer
Journal of Clinical Laboratory Analysis
Allergy
Immunology
Biochemistry
Public Health
Medical Laboratory Technology
Clinical Biochemistry
Hematology
Microbiology
Environmental
Occupational Health
Related publications
Clinical Features of Bim Deletion Polymorphism and Its Relation With Crizotinib Primary Resistance in Chinese Patients With ALK /ROS1 Fusion-Positive Non-Small Cell Lung Cancer
Cancer
Cancer Research
Oncology
Association of BIM Deletion Polymorphism and BIM-γ RNA Expression in NSCLC With EGFR Mutation
Cancer Genomics and Proteomics
Medicine
Biochemistry
Genetics
Molecular Biology
Cancer Research
Phase I Study of Vorinostat With Gefitinib in BIM Deletion Polymorphism/Egfr Mutation Double‐positive Lung Cancer
Cancer Science
Cancer Research
Medicine
Oncology
The Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism Modifies the Clinical Outcome in Patients With Pompe Disease
Genetics in Medicine
Medicine
Genetics
Outcome of Patients With Chronic Myeloid Leukemia With Multiple ABL1 Kinase Domain Mutations Receiving Tyrosine Kinase Inhibitor Therapy
Haematologica
Hematology
The Effect of Vasodilator Therapy on the Clinical Outcome of Patients With Primary Pulmonary Hypertension
Circulation
Cardiovascular Medicine
Physiology
Cardiology
Predicting Clinical Outcome of Therapy-Resistant Prostate Cancer
Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
Association of TP53codon 72 Polymorphism and the Outcome of Adjuvant Therapy in Breast Cancer Patients
Breast Cancer Research
Cancer Research
Oncology
Patient-Specific Molecular Alterations Are Associated With Metastatic Clear Cell Renal Cell Cancer Progressing Under Tyrosine Kinase Inhibitor Therapy
Oncotarget
Oncology
